Analytic variability in immunohistochemistry biomarker studies.
about
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerEGFR soluble isoforms and their transcripts are expressed in meningiomas.Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).Multiplexed ion beam imaging of human breast tumorsDetection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging.From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancerQuantitative measurement of cancer tissue biomarkers in the lab and in the clinic.Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades.EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialCytoplasmic estrogen receptor in breast cancer.EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR.Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.Empirical comparison of color normalization methods for epithelial-stromal classification in H and E imagesThe status of epidermal growth factor receptor in borderline ovarian tumours.Guidelines and considerations for conducting experiments using tissue microarrays.Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.Clinical utility of reverse phase protein array for molecular classification of breast cancer.Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues.PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.Working towards a consensus for antibody validation.Intrinsic indicators for specimen degradation.Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application scheduleHeregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.How difficult is the validation of clinical biomarkers?Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue.Unvalidated antibodies and misleading results.The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.In situ protein detection with enhanced specificity using DNA-conjugated antibodies and proximity ligation.A reference image-based method for optimization of clinical immunohistochemistry.Prognostic significance of NF-κB expression in non-small cell lung cancer: A meta-analysis.The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
P2860
Q28084216-A388EABB-A2EE-4AF8-95D5-9020DF0FA921Q31062214-04811261-C375-4489-AEED-158D37F9D7F9Q33917876-83CB8AC0-F2EB-4512-B45B-9CFA6854DBC8Q33949706-1C092C30-8CCE-47E0-8253-6DD7C7159203Q34809415-4EA8512D-A6B3-49B5-8171-5CD26F154DCFQ35117568-64A815A1-6FD7-4C17-BE6B-08D6265F4202Q35145095-C93D2DE8-E68F-4958-878F-6142078AB0C8Q35167923-ECC529C8-9294-48E5-98E6-5FED3B2EF60DQ35251561-10B318CD-A507-4486-81DE-F06436BFFE34Q35440615-FDED9C33-73B2-4700-93FA-33DB25FBDD08Q35678436-998F97EC-A7F1-4CE8-AEAA-79F57970073EQ35686728-B62028EB-E26C-4405-ABC7-400FC64C26A6Q35699888-B5BCE4FA-0D88-4962-A5E4-5DCFB169057FQ35844968-86F69C2F-E0EA-4070-8FE6-5B0BF1220AA6Q36196817-66D0FE1D-F183-40C9-970D-7F02A9E45C5DQ36547753-980CC3B1-3D86-4BD1-990C-C275FBBFBC42Q36816118-0B4A5F69-D439-4748-AF3C-6677BBFC4964Q36963030-AB6ECF9C-F09A-4496-9C60-E084C91F3974Q38106730-9E1DDBAA-07A6-42FD-B7DB-DE956DE85CBBQ38149813-99B5F9A8-E3BD-4D7B-9092-C2317BDE1E0CQ38383140-5D25D74A-2836-485B-BF09-C1A0E267A19FQ38404913-F96E8BE4-9052-4630-B333-2A55546DD612Q38736925-296A0087-D2C9-4060-9657-2654D2AA18BEQ39061496-2129009F-BA99-40E5-9470-18708787F5E3Q39232322-F5850622-16DB-4CBB-A694-B94D1EFADF75Q39358414-9D73B374-46E2-4102-81E1-CD37A417C383Q39499017-840CEC9E-1D20-4916-8191-1CD6A3AAADEAQ40650002-50D03E6E-31DE-4F1B-B51C-72E7F3CC6973Q42505561-B3A87E82-D4D1-4C42-8611-64F43E64B692Q42971341-6FB2A069-B7A3-4D36-BEED-66021C0DD5A0Q47110861-E74FA62D-B69B-419C-942C-8899A8FDBFC1Q47762917-64A7439F-3E5D-4F7A-88F4-9D4F5A8BF5CEQ48518220-DC956535-0FD2-4881-8CCA-DBFCE2C2A73AQ55025383-5FC40F66-0E3D-45AC-A6F4-A5DFC2A5DEB2Q58601441-7471B3D9-8227-49C3-B8B5-A65F82D8C038
P2860
Analytic variability in immunohistochemistry biomarker studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Analytic variability in immunohistochemistry biomarker studies.
@en
Analytic variability in immunohistochemistry biomarker studies.
@nl
type
label
Analytic variability in immunohistochemistry biomarker studies.
@en
Analytic variability in immunohistochemistry biomarker studies.
@nl
prefLabel
Analytic variability in immunohistochemistry biomarker studies.
@en
Analytic variability in immunohistochemistry biomarker studies.
@nl
P2093
P2860
P1476
Analytic variability in immunohistochemistry biomarker studies
@en
P2093
Allison W Welsh
Camil Liceaga
David L Rimm
Jennifer M Giltnane
Konstantinos N Syrigos
Mark Gustavson
Summar Siddiqui
Valsamo K Anagnostou
P2860
P304
P356
10.1158/1055-9965.EPI-10-0097
P50
P577
2010-03-23T00:00:00Z